Increased positive charge of compounds or agents leads to increased
glomerular filtration, increased binding by positively charged agents by
the cells of the proximal tubules and decreased digestion of the
reabsorbed materials. The present invention concerns the use of non-toxic
positively charged materials to saturate binding sites on the proximal
tubular brush border. If the binding sites on the brush border are
saturated, then there should be decreased binding and absorption of the
toxic agents by the proximal tubular renal cells. Specifically the
invention is the use of combination of therapeutic positively charged
agents comprising one or more of the following compounds; pyridoxal,
niacin, thiamine and their relatively non-toxic analogs, amprolium, and
isoniazid. These compounds are administered prior to the dosing of such
positively charged therapeutics such as Trasylol.RTM. (aprotinin),
cisplatin. or antimicrobiological peptides such as reported in patent
application publication 2005/0065072. The predosing of one or more of the
following compounds; pyridoxal, niacin, thiamine and their relatively
non-toxic analogs, amprolium, and isoniazid inhibits the renal effects of
Trasylol.RTM. (aprotinin), cisplatin or antimicrobiological peptides such
as reported in patent application publication 2005/0065072. Likewise, a
combination of therapeutic positively charged agents comprising one or
more of the following compounds; pyridoxal, niacin, thiamine and their
relatively non-toxic analogs, amprolium, and isoniazid, when administered
with or without quinine for the treatment of malaria will inhibit the
renal effects of malaria or such agents will inhibit renal failure caused
by myoglobin released by crush injury